Harvard Bioscience (HBIO) EBITDA Margin (2010 - 2026)
Harvard Bioscience's (HBIO) quarterly EBITDA Margin came in at 5.66% in Q1 2026, up 22245.0% year-on-year from N/an in Q1 2025, and down 178.51% on a QoQ basis from 7.2% in Q4 2025.
Harvard Bioscience (HBIO) EBITDA Margin (2010 - 2026) Analysis & Trends
Harvard Bioscience (HBIO) has 17 years of EBITDA Margin data on file, last reported at 5.66% in Q1 2026.
- On a quarterly basis, EBITDA Margin rose 22245.0% year-over-year to 5.66% in Q1 2026; TTM through Mar 2026 was 0.1%, a 5854.0% increase from a year earlier, with the FY2025 full-year figure at 56.13%, down 4953.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 5.66%, down from 7.2% in the prior quarter.
- Over the last five years, EBITDA Margin for HBIO reached as high as 13.69% in Q2 2022 and fell as low as 228.11% in Q1 2025.
- Historically, EBITDA Margin has averaged 16.21% across 5 years, with a median of 3.68% in 2023.
- Across the five-year window, EBITDA Margin sank 21881 bps in 2025 and jumped 22245 bps in 2026, its largest moves.
- Year by year, EBITDA Margin stood at 1.61% in 2022, then jumped by 162 bps to 1.0% in 2023, then slumped by 96 bps to 0.04% in 2024, then surged by 15983 bps to 7.2% in 2025, then tumbled by 179 bps to 5.66% in 2026.
- Per Business Quant data, the three most recent EBITDA Margin figures were 5.66% in Q1 2026, 7.2% in Q4 2025, and 0.96% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alcon | 32,734,969.19 Bn | 32,734,967.53 Bn | 1.53 Bn | 98.77% |
| 2 | Intuitive Surgical | 117.50 Bn | 112.41 Bn | 1.96 Bn | 33.60% |
| 3 | Becton Dickinson | 42.93 Bn | 42.11 Bn | 2.15 Bn | 1.97% |
| 4 | Medline | 30.82 Bn | 36.66 Bn | 1.84 Bn | 5.74% |
| 5 | Resmed | 27.90 Bn | 26.23 Bn | 890.98 Mn | 34.92% |
| 6 | West Pharmaceutical Services | 26.76 Bn | 26.23 Bn | 329.20 Mn | 20.53% |
| 7 | Cooper Companies | 15.30 Bn | 15.16 Bn | 735.40 Mn | -2.87% |
| 8 | Solventum | 13.46 Bn | 12.90 Bn | 1.10 Bn | 4.04% |
| 9 | Align Technology | 12.02 Bn | 10.96 Bn | 736.59 Mn | 13.65% |
| 10 | Harvard Bioscience | 28.05 Mn | 20.96 Mn | 12.24 Mn | -5.66% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.66% |
| Dec 31, 2025 | 7.20% |
| Sep 30, 2025 | 0.96% |
| Jun 30, 2025 | -4.00% |
| Mar 31, 2025 | -228.11% |
| Dec 31, 2024 | 0.04% |
| Sep 30, 2024 | -8.53% |
| Jun 30, 2024 | -8.96% |
| Mar 31, 2024 | -9.30% |
| Dec 31, 2023 | 1.00% |
| Sep 30, 2023 | -3.68% |
| Jun 30, 2023 | 2.77% |
| Mar 31, 2023 | 5.83% |
| Dec 31, 2022 | -1.61% |
| Sep 30, 2022 | -13.97% |
| Jun 30, 2022 | 13.69% |
| Mar 31, 2022 | -23.32% |
| Dec 31, 2021 | 5.14% |
| Sep 30, 2021 | 1.85% |
| Jun 30, 2021 | 0.20% |